Ser306

Site Information
RNyNkQAsEQNWANy SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 465459

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 )
Disease tissue studied:	breast cancer ( 2 , 3 , 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 2 ) , lung cancer ( 5 , 6 , 9 ) , non-small cell lung cancer ( 5 , 6 , 9 ) , non-small cell lung adenocarcinoma ( 6 ) , neuroblastoma ( 4 ) , ovarian cancer ( 2 )
Relevant cell line - cell type - tissue:	breast ( 1 , 2 ) , BT-549 (breast cell) ( 5 ) , H2077 (pulmonary) ( 5 ) , H322M (pulmonary) ( 5 ) , HCC2279 (pulmonary) ( 5 ) , HES-3 ('stem, embryonic') ( 7 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 3 ) , HMLER ('stem, breast cancer') ( 3 ) , HUES-9 ('stem, embryonic') ( 8 ) , LOU-NH91 (squamous) ( 5 ) , lung ( 6 , 9 ) , MDA-MB-231 (breast cell) ( 5 ) , NB10 (neural crest) ( 4 ) , NCI-H2172 (pulmonary) ( 5 ) , NCI-H460 (pulmonary) ( 5 ) , NPC (neural crest) ( 4 ) , ovary ( 2 ) , TERT20 ('stem, mesenchymal') ( 10 )

Upstream Regulation
Treatments:	ischemia ( 2 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
3	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
4	DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513 24349301 Curated Info
5	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
6	Ren H (2011) CST Curation Set: 11785; Year: 2011; Biosample/Treatment: cell line, RP102/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
7	Ding VM, et al. (2011) Tyrosine phosphorylation profiling in fgf-2 stimulated human embryonic stem cells. PLoS One 6, e17538 21437283 Curated Info
8	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
9	Ren H (2009) CST Curation Set: 6962; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
10	Thingholm TE, et al. (2008) TiO2-Based Phosphoproteomic Analysis of the Plasma Membrane and the Effects of Phosphatase Inhibitor Treatment. J Proteome Res 7, 3304-3313 18578522 Curated Info